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Upregulation of xanthine oxidoreductase (XOR) increases vascular reactive oxygen species (ROS) levels
and contributes to nitroso-redox imbalance. However, XOR can generate nitric oxide (NO) from nitrite,
and increased superoxide could inactivate NO formed from nitrite. This study tested the hypothesis that
XOR contributes to the cardiovascular effects of nitrite in renovascular hypertension, and that treatment
with the antioxidant tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl) improves XOR-mediated
effects of nitrite. Blood pressure was assessed weekly in two-kidney one-clip (2K1C) and control rats.
After six weeks of hypertension, the relaxing responses to nitrite were assessed in aortic rings in the
presence of the XOR inhibitor oxypurinol (or vehicle), either in the absence or in the presence of tempol.
Moreover, in vivo hypotensive responses to nitrite were also examined in the presence of oxypurinol (or
vehicle) and tempol (or vehicle). Aortic XOR activity and expression were evaluated by ﬂuorescence and
Western blot, respectively. Vascular ROS production was assessed by the dihydroethidium assay. 2K1C
hypertensive rats showed increased aortic XOR activity and vascular ROS production compared with
control rats. Oxypurinol shifted the nitrite concentration–response curve to the right in aortic rings from
2K1C rats (but not in controls). Oxypurinol also attenuated the hypotensive responses to nitrite in 2K1C
rats (but not in controls). These functional ﬁndings agree with increased aortic and plasma XOR activity
found in 2K1C rats. Tempol treatment enhanced oxypurinol-induced shift of the nitrite concentration–
response curve to the right. However, antioxidant treatment did not affect XOR-mediated hypotensive
effects of nitrite. Our results show that XOR is important to the cardiovascular responses to nitrite in
2K1C hypertension, and XOR inhibitors commonly used by patients may cancel this effect. This ﬁnding
suggests that nitrite treatment may not be effective in patients being treated with XOR inhibitors.
Moreover, while tempol may improve the vascular responses to nitrite, antihypertensive responses are
not affected.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Xanthine oxidoreductase (XOR) is a molybdoﬂavin enzyme that
catalyzes the oxidation of hypoxanthine to xanthine, and xanthine
to uric acid in the metabolic pathway of purine degradation [1, 2].
It exists in two interconvertible forms: xanthine dehydrogenase
(XDH), which is the prevalent form under physiological conditions
in vivo [3], and xanthine oxidase (XO), which is derived from XDHB.V. This is an open access article u
gy, Ribeirao Preto Medical
0, 14049-900 Ribeirao Preto,by posttranslational modiﬁcations [4]. Increased production of
superoxide by XOR increases tissue levels of this free radical and
other reactive oxygen species (ROS), thus contributing to nitroso-
redox imbalance in several disease conditions including hy-
pertension [5–7]. Indeed, upregulated vascular XOR activity has
been shown in animal models of hypertension including sponta-
neous hypertensive rats (SHR) [8] and deoxycorticosterone-salt
(DOCA-salt) hypertension [9].
In addition to its prooxidant properties, XOR converts nitrite
anion into nitric oxide (NO) under particular circumstances, thus
contributing to the beneﬁcial effects of this vasoactive NO meta-
bolite [10–12]. In this regard, nitrate and nitrite are now described
as the major sources of NO independent of the classical enzymatic
NO formation from L-arginine [13–16]. Although they were initiallynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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both are recycled to NO by the nitrate-nitrite-NO pathway [13–15].
This is achieved by pH-dependent reduction of nitrite to NO in the
stomach [18,19] or by enzymatic reduction of nitrite to NO by
enzymes with nitrite-reductase activity, particularly XOR [10,11].
Although XOR can convert nitrite into NO and contribute to the
antihypertensive effects of nitrite, the relevance of this reaction in
hypertension remains unclear. While increased vascular XOR ex-
pression contributes to the antihypertensive effects of nitrite in
the Nω-nitro-L-arginine methyl ester (L-NAME) hypertension
model [20], this is apparently not the case in the SHR model [21].
In particular, no previous study has investigated the participation
of XOR in the effects of nitrite in the two-kidney one-clip (2K1C)
hypertension model, which resembles human renovascular hy-
pertension [22]. Activation of renin-angiotensin system increases
angiotensin II levels in this model of hypertension [23,24], and
angiotensin II is a major XOR activator [25,26]. Determining how
important XOR is to the antihypertensive responses to nitrite may
inﬂuence the prescription of widely used XOR inhibitors such as
allopurinol [27], should nitrite therapy be incorporated to the
therapy of clinical hypertension in the future.
Another important issue associated with increased XOR activity
in hypertension is that XOR-derived superoxide may readily in-
activate nitrite-derived NO [28], thereby impairing the anti-
hypertensive effects of nitrite. This suggestion is supported by
previous studies showing that XOR bound to vascular endothelium
impairs NO-dependent signaling in smooth muscle cells [29].
This study aimed at examining the relevance of XOR to the
vasodilatory and hypotensive effects of sodium nitrite in 2K1C
hypertension. In addition, we also tested the hypothesis that the
administration of an antioxidant (tempol) could improve the im-
paired nitroso-redox balance of hypertension and enhance XOR-
dependent vasodilatory and hypotensive effects of nitrite.2. Materials and methods
2.1. Animals and hypertension model
The present study was performed in accordance with National
Institutes of Health (NIH; USA) guidelines. All experimental proto-
cols with animals were approved by our Institutional Animal Care
and Use Committee of the Ribeirao Preto Medical School, University
of Sao Paulo. Male Wistar rats (180–200 g) obtained from the colony
at the University of Sao Paulo (Ribeirao Preto Campus, Brazil) were
maintained on a 12-h light/dark cycle at room temperature (22–
25 °C) with free access to standard rat chow and water.
Hypertension (two-kidney, one clip; 2K1C) was induced as
previously described [30,31]. Brieﬂy, the rats were anesthetized
with ketamine (100 mg/kg; i.p.) and xylazine (10 mg/kg; i.p.) and
the left renal artery was clipped with a silver clip (0.2 mm). As
normotensive controls, sham operated rats underwent the same
surgical procedure without placement of the renal artery clip.
After surgery, the nonsteroidal anti-inﬂammatory ﬂunixine me-
glumine (2.5 mg/kg, sc, Banamine; Schering Plough, Brazil) was
administered. Systolic blood pressure (SBP) was measured weekly
by tail-cuff plethysmography [30,31]. To minimize the effects of
stress induced by this method on blood pressure measurement,
the animals were trained for a week before surgery. The rats were
considered hypertensive when SBP 4160 mmHg two weeks after
the surgery [30,31].
2.2. Assessment of xanthine oxidoreductase activity
Plasma and aortic XOR activity was measured with a horse-
radish peroxidase-linked commercial kit (Cayman Chemical Co.,Ann Arbor, MI, USA) following the manufacturer's instructions. In
brief, plasma and aorta homogenates were added to working so-
lution containing ADHP (10-acetyl-3,7-dihydroxyphenoxazine),
xanthine and horseradish peroxidase and the H2O2 production
was measured. Some experiments were performed in the presence
of the XOR inhibitor oxypurinol (3104 mol/l). The reactions
were incubated for 45 min at 37 °C. Fluorescence readings were
made in duplicate in a 96-well plate at Ex/Em¼535/590 nm using
100-μl total volume per well. The results of XOR activity in μU/ml
(plasma) or mU/mg protein (aorta) were plotted with respect to a
standard curve obtained with known concentrations of XOR.
2.3. Western blotting analysis of vascular xanthine oxidoreductase
expression
To evaluate XOR expression in aortas from sham and 2K1C rats,
Western blotting was performed as described previously [20,32],
with primary antibodies (1:500) directed against XOR (code sc-
20991, Santa Cruz Inc., Santa Cruz, CA, USA), and the expression was
corrected by β-actin expression (dilution 1:10,000, codeMAB1501,
Millipore, Temecula, CA, USA).
2.4. Functional studies to assess the effects of increased vascular XOR
activity on the responses to nitrite
Given the fact that XOR can convert nitrite into NO and that
hypertension increases XOR activity, functional experiments were
performed to assess whether this biochemical alteration increases
the vascular responses to sodium nitrite.
Firstly, we examined whether increased aortic XOR activity
increases the vascular responses of isolated aortic rings to nitrite.
Six weeks after the surgery to clip the renal artery, sham and 2K1C
rats were euthanized under anesthesia with ketamine (100 mg/kg;
i.p.) and xylazine (10 mg/kg; i.p.). The thoracic aorta was carefully
excised, cleaned of adherent connective tissues and fat, and cut
into 4 mm long rings. The aortic rings were mounted for isometric
tension recording and placed in organ bath chambers (5 ml) con-
taining modiﬁed Krebs salt solution with the following composi-
tion (mmol/l): NaCl 130, CaCl2 1.6, MgSO4 1.2, KH2PO4 1.2, KCl 4.7,
NaHCO3 14.9, glucose 5.5 [31]. The solution was maintained at
37 °C and pH 7.4 and was continuously aerated with 95% O2 and 5%
CO2. The system was connected to an isometric force transducer
(Letica Scientiﬁc Instruments, Barcelona, Spain) to measure chan-
ges in isometric tone, which were recorded on a computer system
using the LabChart version 4.04, PowerLab ADInstruments (2000)
program. The rings were stretched to a basal tension of 1.5 g
during a 60 min equilibration period, with the bath ﬂuid being
changed every 15–20 min. After equilibration, endothelial integrity
was evaluated by the degree of relaxation induced by acetylcho-
line (106 mol/l) following contraction induced by phenylephrine
(107 mol/l). Aortic rings with intact functional endothelium were
precontracted with phenylephrine (107 mol/l) and relaxing re-
sponse curves to cumulative concentrations (from 3108 to
102 mol/l) of sodium nitrite were constructed in the presence of
the XOR inhibitor oxypurinol (3104 mol/l) or vehicle. The re-
sults were expressed as pD2 (the negative logarithm of the con-
centration producing half maximum effect) and maximum effect
in response to sodium nitrite.
Secondly, we examined whether increased XOR activity en-
hances the hypotensive responses to the acute administration of
sodium nitrite in unanesthetized freely moving rats. To assess
invasive mean arterial blood pressure (MAP), the animals were
anesthetized with ketamine (100 mg/kg; i.p.) and xylazine (10 mg/
kg; i.p.), and both the femoral artery and vein were cannulated (3-
cm segment of a PE-10 tube connected to 14 cm of a PE-50 tubing;
Clay Adams, Parsippany, NJ, USA) 24 h before MAP recording. The
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through the back of the neck. Flunixine meglumine (2.5 mg/kg, sc,
Banamine; Schering Plough, Brazil) was administered for post-
operative analgesia. After 12 h of fasting, the arterial cannula was
connected to a pressure transducer and the MAP was recorded in
freely moving rats using a data acquisition system (MP150CE;
Biopac Systems Inc. CA, USA) connected to a computer (Ac-
knowledge 3.2, for Windows). We then examined the hypotensive
responses to intravenously infused sodium nitrite (1, 3, 10, 30, and
100 μmol/kg) in sham and 2K1C rats that received vehicle (NaOH
0.15 mol/l; 25 μl/min) or oxypurinol (25 mg/kg; 25 μl/min) in-
travenously 15 min before the nitrite infusions started [20]. Each
cumulative doses of sodium nitrite was infused every 15 min, and
the maximum changes in MAP were evaluated.
2.5. Assessment of vascular reactive oxygen species (ROS) production
To assess vascular oxidative stress, aortic ROS production was
measured by using dihydroethidium (DHE), which is a ROS-sensitive
ﬂuorescent dye. Aortic cryosections (5 mm thick) were incubated
with DHE (10 mmol/l) for 30 min at room temperature. The sections
were examined by ﬂuorescence microscopy (Leica Imaging Systems
Ltd., Cambridge, England) at x400 using λ¼525 nm excitation and
λ¼605 nm emission, which is not speciﬁc to detect only superoxide.
Red ﬂuorescence from 20 ﬁelds around the vessel was evaluated
using image software imageJ (http://rsbweb.nih.gov/ij/) as previously
described [33]. In some experiments, the aortas were pretreated for
1 h with tempol (104 mol/l, a superoxide dismutase analogue), or
diphenyl iodonium (DPI 10 mmol/l, a ﬂavoprotein inhibitor), or Tiron
(1 mmol/l, a superoxide scavenger).
2.6. Functional studies to examine whether reduction in oxidative
stress enhances XOR-mediated vascular responses to nitrite
Given that oxidative stress associated with hypertension decreases
NO bioavailability NO [6,28,29], we examined whether reduction of
oxidative stress with tempol increases the vascular responses to nitrite
that are mediated by XOR. Using the same methodology as detailed
above, aortic rings from 2K1C rats were incubated with the tempol
(104 mol/l) and the oxypurinol (3104 mol/l) or vehicle (control
experiments). After precontraction with phenylephrine (107 mol/l),
relaxing response curves to cumulative concentrations (from
3108 mol/l to 102 mol/l) of sodium nitrite were constructed. Fi-
nally, to assess whether oxidative stress affects the vasorelaxing effects
of sodium nitrite mediated by XOR, we compared the changes in pD2
produced by oxypurinol (pD2 with vehicle minus pD2 with oxypur-
inol) in aortic rings from 2K1C rats in the presence and the absence of
tempol.
In addition, we used the same experimental conditions detailed
above to examine whether reduction of oxidative stress with tempol
improves the contribution of XOR to the hypotensive effects of so-
dium nitrite. Therefore 2K1C hypertensive rats received tempol
(18 mg/kg) by gavage [34] and, 15 min later, they received infusions
of vehicle (NaOH 0.15 mol/l; 25 μl/min) or oxypurinol (25 mg/kg;
25 μl/min) for 10 min. After 15 min, the rats received cumulative
doses of sodium nitrite (1, 3, 10, 30, and 100 μmol/kg) intravenously.
Nitrite doses were injected every 15 min, and the maximum changes
in MAP were evaluated. We then compared the area under the curve
(AUC) of the changes in MAP induced by sodium nitrite in the pre-
sence or in the absence of tempol and oxypurinol (or vehicle).
2.7. Drugs and solutions
All drugs and reagents were purchased from Sigma Chemical Co.
(St Louis, MO, USA) and all solutions were prepared immediately
before use.2.8. Statistical analysis
The results are expressed as means7SEM. The comparisons
between groups were assessed by unpaired t test or by Mann
Whitney test, and by two-way analysis of variance, using Bonferroni
correction where appropriated (GraphPad Prism Software, San
Diego, CA). A probability value o0.05 was considered signiﬁcant.3. Results
3.1. Renovascular hypertension increases vascular XOR activity
As expected, SBP increased in 2K1C rats compared with sham
rats (189730 versus 119722 mmHg at the sixth week of hy-
pertension; Po0.05). Because XOR is an important pro-oxidant
enzyme, we examined whether 2K1C hypertension increases
vascular and circulating XOR activity. We found increased XOR
activity in plasma (Fig. 1A; 22773 versus 20675 μU/ml; Po0.05)
and in aortas (Fig. 1B; 97724 versus 3279 mU/mg protein;
Po0.05) from 2K1C rats compared with sham rats. Control ex-
periments using the XOR inhibitor oxypurinol showed that this
inhibitor blunted 485% of vascular XOR activity measured in
aortic rings from 2K1C rats (Fig. 1C; Po0.05). The analysis of XOR
expression in the aortas showed only a trend for increased aortic
XOR expression in 2K1C compared to sham rats (Fig. 1D and E; not
signiﬁcant).
3.2. Xanthine oxidoreductase contributes to the vasodilatory and
antihypertensive effects of sodium nitrite in renovascular
hypertension
Because we observed increased plasma and vascular XOR ac-
tivity in 2K1C rats, we examined whether increased XOR activity
would enhance the vascular responses to nitrite, which is converted
into NO by XOR. Indeed, incubation of aortic rings from 2K1C rats
with the XOR inhibitor oxypurinol shifted the concentration-effect
curve in response to sodium nitrite to the right (Fig. 2A and B; pD2
vehicle¼4.270.2 versus pD2 oxypurinol¼3.770.1; Po0.05)
without signiﬁcantly changing the maximum effect (Fig. 2A and C;
Emax vehicle¼9872% versus Emax oxypurinol¼9871%; P40.05).
However, in contrast with aortic rings from 2K1C rats, XOR inhibi-
tion with oxypurinol produced no change in pD2 (Fig. 2A and B;
vehicle¼4.370.1 versus oxypurinol¼4.470.1; P40.05) and in
Emax (Fig. 2A and C; vehicle¼9571%, versus oxypurinol¼9671%;
P40.05) values in aortic rings from sham-operated animals, thus
suggesting that XOR contributes to the vasodilatory effects of so-
dium nitrite in 2K1C hypertension, but not in normotensive sham
animals.
To further validate the role of XOR in the responses to nitrite
therapy, we investigated in vivo implications of increased XOR
activity in 2K1C hypertension. Blood pressure responses to in-
travenous sodium nitrite were assessed in sham and 2K1C rats
after XOR inhibition with oxypurinol or vehicle treatment. Under
control conditions (vehicle treatment), sodium nitrite produced
dose-dependent hypotension in unanesthetized freely moving
rats, both in normotensive and hypertensive rats (Fig. 3A and B;
Po0.05). However, while pretreatment with oxypurinol had no
effects on the hypotensive responses to nitrite in sham-operated
animals (Fig. 3A; P40.05), it attenuated those responses in 2K1C
hypertensive rats, particularly when the highest nitrite dose
(100 μmol/kg) was infused (Fig. 3B; 2674 mmHg for vehicle-
treated versus 872 mmHg for oxypurinol-treated; Po0.05).
These results suggest an important role for XOR in the hypotensive
responses to nitrite in 2K1C hypertensive rats, and agree with the
results found with isolated vessels.
Fig. 1. Xanthine oxidoreductase (XOR) activity and expression in sham and 2K1C rats. Panel A shows plasma XOR activity (μU/ml) and panel B shows aortic XOR activity (μU/
μg protein) in sham and 2K1C rats. Panel C shows percentage of inhibition of XOR activity produced by oxypurinol (3104 mol/l) in aortas from 2K1C rats in relation to
aortas from 2K1C rats in the absence of this inhibitor. Panel D shows a graph with the densitometric analysis for aortic XOR normalized by β-actin content. Panel E shows a
representative western blotting gel showing the aortic expression of XOR in sham and 2K1C rats. Data are shown as mean7S.E.M. (n¼5–7/group in A; n¼4–6/group in B;
n¼3–4/group in C; n¼8–9/group in D). *Po0.05.
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but not the hypotensive responses to nitrite in 2K1C hypertension
The vascular production of ROS was examined in aortas by
using the sensitive ﬂuorescent dye dihydroethidine (DHE). In
agreement with previous studies [5,31,32], we found a 44-fold
increase in ROS levels in aortas from 2K1C as compared with sham
rats (Fig. 4A and B; Po0.05). Quantiﬁcation of DHE ﬂuorescence in
control experiments using aortas from hypertensive rats showed
that the superoxide dismutase analogue tempol, or the ﬂavopro-
tein inhibitor DPI, or the superoxide scavenger tiron, blunted the
DHE signal by 480% (Fig. 4B and C; Po0.05).
Because oxidative stress reduces NO activity [6,28,29], XOR-
derived superoxide may readily inactivate nitrite-derived NO [28]
and impair the contribution of XOR to the vasodilator effects of
sodium nitrite. We used aortas from 2K1C hypertensive rats to
assess how the antioxidant tempol modiﬁes XOR-mediated vaso-
dilatory effects of sodium nitrite shown in Fig. 2. Interestingly,
experiments carried out in the presence of tempol showed that
pretreatment with oxypurinol shifted the concentration-effect
curve in response to sodium nitrite to the right (Fig. 5A and B; pD2tempolþvehicle¼4.570.1 versus pD2 tempolþoxypurinol¼
3.770.1; Po0.05) without signiﬁcant changes in the maximum
effect (Fig. 5A and C; Emax tempolþvehicle¼10171% versus Emax
tempolþoxypurinol¼10572%; P40.05).
We then compared the contribution of XOR to the vasodilatory
effects of nitrite under control conditions (incubation with vehicle)
with those found in the presence of the tempol (Fig. 6). The con-
tribution of XOR to the effects of nitrite was assessed by calculating
the decreases in pD2 produced by oxypurinol (ΔpD2ox¼pD2
vehicle–pD2 oxypurinol). Therefore, the comparison of ΔpD2ox va-
lues obtained under control conditions with those obtained in the
presence of the tempol could reﬂect how oxidative stress impairs
XOR-mediated NO production and the corresponding vasodilatory
effects of nitrite. We found that the Δ pD2ox was more pronounced
in the presence of tempol than in the absence of this drug (Fig. 6;
0.8170.11 versus 0.4970.09, respectively; Po0.05), suggest-
ing that antioxidant treatment protects NO formed by XOR by
preventing NO-superoxide reaction, thus enhancing the vasodila-
tory effects of sodium nitrite in 2K1C hypertension.
To further examine relevant implications of the vascular ﬁnd-
ings above, we studied how XOR-mediated hypotensive responses
Fig. 2. Effects of xanthine oxidoreductase (XOR) inhibition on the vasodilator effects of sodium nitrite in aortic rings from sham and 2K1C rats. Panel A shows relaxing
response curves to cumulative concentrations of sodium nitrite in the presence of the XOR inhibitor oxypurinol (3104 mol/l) or vehicle (NaOH, 0.09%). Panel B shows the
pD2 values (negative logarithm to base 10 of the molar concentration of sodium nitrite that produces 50% of the maximal effect), while Panel C shows the maximal responses
to sodium nitrite. Data are shown as mean7S.E.M. (n¼6–7/group). *Po0.05 versus 2K1C Vehicle.
Fig. 3. : Changes in mean arterial pressure (MAP) measured in unanesthetized free-moving sham (Panel A) and 2K1C (Panel B) rats in response to increasing doses of sodium
nitrite in the presence of the xanthine oxidoreductase inhibitor oxypurinol (25 mg/kg) or vehicle (NaOH, 0.15 mol/l). Data are shown as mean7S.E.M. (n¼5–7/group).
*Po0.05 for Oxypurinol versus Vehicle.
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In the presence of tempol, oxypurinol blunted the hypotensive
responses to sodium nitrite, particularly when the highest doses
(30 and 100 μmol/kg, Fig. 7A) were used. Then we compared the
AUC of the changes in MAP induced by sodium nitrite in 2K1C
hypertensive rats pretreated with tempol or vehicle, either in the
presence or in the absence of oxypurinol (Fig. 7B). While tempol
produced a small (not signiﬁcant) improvement in the hypotensive
responses to sodium nitrite in vehicle pretreated rats (Fig. 7B;
P40.05) as previously reported [34], oxypurinol blunted nitrite-
induced hypotension to a similar extent in the presence versus in
the absence of tempol (Fig. 7B; Po0.05), thus suggesting that
oxidative stress does not affect the contribution of XOR to hypo-
tensive responses to nitrite.4. Discussion
This is the ﬁrst study to show that vascular XOR contributes to
the vasodilatory and hypotensive effects of sodium nitrite in re-
novascular hypertension. This ﬁnding is very important because it
suggests that XOR inhibition prevents antihypertensive effects ofnitrite in the 2K1C animal model of hypertension, which re-
sembles human renovascular hypertension [22]. Another im-
portant ﬁnding is that tempol improves XOR-dependent vasodi-
latory effects of nitrite, suggesting a dual role for XOR in the
pharmacology of nitrite. This result suggests that while XOR con-
tributes to vasorelaxing effects of nitrite, its activity also con-
tributes to nitroso-redox imbalance attenuating the vascular re-
sponses to nitrite-derived NO.
Nitrite used to be considered as a relatively inactive oxidation
product of NO [17]. However, this view has changed dramatically
in the last few decades, and nitrite is now regarded as an im-
portant source of NO independent of the classical enzymatic NO
formation from L-arginine [13–16], and a candidate in the phar-
macotherapy of cardiovascular diseases, especially hypertension.
In fact, there is strong experimental evidence that nitrite lowers
blood pressure in different animal models of hypertension in-
cluding SHR [35], L-NAME [20,36,37], DOCA-salt [9] and 2K1C
hypertension [32,37].
The mechanisms explaining the antihypertensive effects of ni-
trite remain poorly understood [38]. In this respect, XOR has been
implicated in NO generation from nitrite [20,21], particularly in
hypertension because XOR up-regulation has been shown in
Fig. 4. Evaluation of reactive oxygen species (ROS) levels in aortic rings from sham and 2K1C rats by dihydroethidium (DHE) ﬂuorescence. Panel A shows representative
photomicrographs (x400) with red ﬂuorescence of DHE-aortic cryosections. Panel B shows the quantiﬁcation of aortic DHE ﬂuorescence in sham and 2K1C rats in the
presence and the absence of tempol (104 mol/l, a superoxide dismutase analogue). Panel C shows the quantiﬁcation of aortic DHE ﬂuorescence in positive control ex-
periments using aortas from 2K1C rats in the presence of diphenyl iodonium (DPI 10 mmol/l, a ﬂavoprotein inhibitor) and Tiron (1 mmol/l, a superoxide scavenger). Data are
shown as mean7S.E.M. (n¼5–8/group). *Po0.05 versus Sham and 2K1CþTempol. #Po0.05 versus 2K1C.
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DOCA-salt [9,39]. However, few studies have reported contrasting
results with respect to the participation of XOR in antihypertensive
effects of nitrite [20,21]. While vascular XOR contributes to the
acute hypotensive effects of nitrite in L-NAME hypertension [20],
Ghosh et al. showed that erythrocytic XOR is more relevant to this
effect, without the involvement of vascular XOR [21]. In the pre-
sent study, we found increased vascular XOR activity and ROS le-
vels in 2K1C hypertensive rats that may result of increased an-
giotensin II levels, a potent XOR activator [25,26]. Consistent with
increased vascular XOR activity in hypertension, treatment with
the XOR inhibitor oxypurinol impaired the vasodilatory responses
of aortic rings from 2K1C rats to nitrite. These functional responses
were further conﬁrmed in vivo by assessing blood pressureresponses. Interestingly, oxypurinol blunted the hypotensive re-
sponses to nitrite in 2K1C rats, particularly at the highest doses.
Together, our ﬁndings suggest that increased vascular XOR activity
improves the vascular and hypotensive responses to nitrite. If
patients with clinical hypertension present pathophysiological al-
terations similar to those reported here, it is possible that the wide
use of XOR inhibitors such as allopurinol [27] may cancel anti-
hypertensive effects of nitrite. Clinical studies are needed to test
this possibility.
In agreement with previous studies [5,31,33], we observed in-
creased ROS levels in aortas from 2K1C rats compared with sham
rats. While the main goal of the present study was not to detect a
speciﬁc oxidant in 2K1C hypertension, and for this reason we used
the term ROS in this manuscript [40], it is reasonable to suggest
Fig. 5. Contribution of xanthine oxidoreductase (XOR) to the vasodilator effects of sodium nitrite in aortic rings from 2K1C rats increases in the presence of the antioxidant
tempol. Panel A shows relaxing response curves to cumulative concentrations of sodium nitrite in the presence of the antioxidant tempol (104 mol/l) plus the XOR inhibitor
oxypurinol (3104 mol/l) or tempol (104 mol/l) plus vehicle (NaOH, 0.09%). Panel B shows the pD2 values (negative logarithm to base 10 of the molar concentration of
sodium nitrite that produces 50% of the maximal effect), while Panel C shows the maximal responses to sodium nitrite. Data are shown as mean7S.E.M. (n¼4/group).
*Po0.05.
Fig. 6. Antioxidant treatment improves XOR-mediated NO formation and vasodi-
latory effects of nitrite. This ﬁgure shows negative changes in pD2 produced by
oxypurinol (ΔpD2ox¼pD2 vehicle–pD2 oxypurinol) in aortic rings from 2K1C rats
under control conditions (vehicle) and in the presence of the antioxidant tempol.
Data are shown as mean7S.E.M. (n¼4–6/group). *Po0.05.
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production, which readily inactivates nitrite-derived NO [28, 29],
possibly impairing the responses to this NO metabolite. Thereforewe examined whether the administration of tempol improves
nitroso-redox balance of hypertension and enhances XOR-depen-
dent vasodilatory and hypotensive effects of nitrite. Interestingly,
treatment with tempol decreased vascular ROS levels and im-
proved XOR-mediated vasodilatory responses to nitrite in 2K1C
hypertension, thus suggesting that tempol improved nitrite-de-
rived NO bioavailability and vasorelaxing responses. However, in
contrast with the vascular responses to nitrite, antioxidant treat-
ment was not associated with improved XOR-mediated hypoten-
sive responses to nitrite. These results may reﬂect the idea hypo-
tensive responses to nitrite may involve other mechanisms than
the simple XOR-mediated generation of NO from nitrite. In addi-
tion, it is clear that blood pressure regulation involves a variety of
determinants affecting cardiac output and total peripheral re-
sistance, and therefore blood pressure responses are much more
complex than vascular responses. Another possible explanation for
the differential effects of tempol between the hypotensive re-
sponses and the aortic studies is that blood pressure responses
in vivowere assessed in freely moving rats breathing room air (21%
O2), whereas aortic studies were carried out with 95% O2 in the
vessel bath. Under physiologic conditions (21% O2) XOR reduces O2
mostly to H2O2, whereas superoxide is the predominant product
when O2 concentrations increase to near 100% [41,42]. Therefore,
at very high O2 tension in the vessel bath, one would expect much
greater superoxide formation from XOR than under in vivo con-
ditions [41,42], and this artiﬁcial enhancement of superoxide le-
vels could favor tempol to produce more observable effects.
In conclusion, our results show that XOR activity is very re-
levant to both vasorelaxing and antihypertensive responses to
nitrite in renovascular hypertension, and the use of XOR inhibitors
may cancel both effects. This ﬁnding suggests that nitrite treat-
ment may not be effective in patients being treated with XOR in-
hibitors. However, clinical implications of these ﬁndings should be
explored in future studies. Moreover, while tempol and other an-
tioxidants may improve the vascular responses to nitrite, the an-
tihypertensive responses are not affected.
Fig. 7. Antioxidant tempol does not enhance the contribution of xanthine oxidoreductase (XOR) to the hypotensive responses to sodium nitrite in 2K1C rats. Panel A shows
the changes in mean arterial pressure (MAP) measured in unanesthetized free-moving 2K1C rats in response to increasing doses of sodium nitrite in the presence of the
antioxidant tempol (18 mg/kg) plus the XOR inhibitor oxypurinol (25 mg/kg) or tempol (18 mg/kg) plus vehicle (NaOH, 0.15 mol/l). Panel B shows the area under the curve
(AUC) of the changes in MAP induced by sodium nitrite in the presence or in the absence of tempol plus oxypurinol (or vehicle). Data are shown as mean7S.E.M. (n¼5–7/
group). *Po0.05 for Oxypurinol versus Vehicle.
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